United Therapeutics Corporation (UTHR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

United Therapeutics Corpo... (UTHR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

364.56

1.68 (0.46%)

At close: Jan 14, 2025, 3:59 PM

364.70

0.04%

After-hours Jan 14, 2025, 04:00 PM EST

undefined% (undefined)

Bid	283.5
Market Cap	16.28B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	22.75
PE Ratio (ttm)	16.02
Forward PE	n/a
Analyst	Strong Buy

Ask	375
Volume	200,981
Avg. Volume (20D)	326,981
Open	361.97
Previous Close	362.88
Day's Range	357.55 - 366.48
52-Week Range	208.62 - 417.82
Beta	undefined

About UTHR

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its commercial therapies include Remodulin to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Tyvaso, an inhaled formulation of prostacyclin a...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 17, 1999

Employees 1,168

Stock Exchange NASDAQ

Ticker Symbol UTHR

Website https://www.unither.com

Analyst Forecast

According to 14 analyst ratings, the average rating for UTHR stock is "Strong Buy." The 12-month stock price forecast is $344, which is a decrease of -5.64% from the latest price.

Buy 78.57%

Hold 14.29%

Sell 7.14%

Stock Forecasts

Next Earnings Release

United Therapeutics Corporation is scheduled to release its earnings on Feb 19, 2025, before market opens.
Analysts project revenue of $734.45M, reflecting a 19.48% YoY growth and earnings per share of 6.62, making a 51.83% increase YoY.

Why Price Moved

4 months ago · Source

+3.04%

United Therapeutics shares are trading higher afte... Unlock content with Pro Subscription

5 months ago · Source

-7.18%

United Therapeutics shares are trading lower after the company reported mixed Q2 financial results.

News

4 days ago · zacks.com

Here's Why United Therapeutics (UTHR) is a Strong Growth Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

5 days ago · zacks.com

Are Medical Stocks Lagging United Therapeutics (UTHR) This Year?

Here is how United Therapeutics (UTHR) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.

5 days ago · zacks.com

Here's Why United Therapeutics (UTHR) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

6 days ago · zacks.com

UTHR vs. STVN: Which Stock Is the Better Value Option?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of United Therapeutics (UTHR) and Stevanato Group (STVN). But which of these two stocks is more attractive to...

1 week ago · businesswire.com

United Therapeutics Corporation to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Dr. Martine Rothblatt, Chairperso...

2 weeks ago · seekingalpha.com

The Zen Ten - My Top Picks For 2025

I've been publishing the Zen Ten list since 2008, consistently beating the market by an average of 9.1% per year since 2000. My methodology involves a rigorous three-step screening process using Zacks...

2 weeks ago · zacks.com

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

3 weeks ago · zacks.com

Why United Therapeutics (UTHR) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

1 month ago · zacks.com

Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?

United Therapeutics (UTHR) reported earnings 30 days ago. What's next for the stock?

2 months ago · seekingalpha.com

United Therapeutics: Competitive Advantages At Such Cheap Multiples Scream Buy

UTHR's competitive advantages, including high returns on capital and successfully recycling of profits, support a bullish outlook. United Therapeutics' Q3 FY '24 earnings showed strong growth across m...

2 months ago · seekingalpha.com

United Therapeutics Expands Into Organ Transplants, But Tyvaso's Legal Battles Loom

Despite legal challenges and exclusivity risks, United Therapeutics is a leader in PAH treatments, with Tyvaso being the primary revenue driver. UTHR is innovating in organ transplantation and bioengi...

2 months ago · seekingalpha.com

United Therapeutics: One To Believe In Despite Competitive Threats

United Therapeutics Corporation's stock has surged over 300% since my 2020 “Buy” rating, driven by strong sales of Tyvaso DPI and other PAH treatments. Despite facing generic competition, United has m...

2 months ago · businesswire.com

United Therapeutics Corporation to Present at the UBS Global Healthcare Conference

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Patrick Poisson, Executive Vice P...

2 months ago · zacks.com

United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 months ago · zacks.com

United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 months ago · zacks.com

United Therapeutics Q3 Earnings & Sales Beat Estimates

UTHR reports better-than-expected results in third-quarter 2024 on the back of strong demand for its treprostinil medications, especially Tyvaso.

2 months ago · seekingalpha.com

United Therapeutics Corporation (UTHR) Q3 2024 Earnings Call Transcript

United Therapeutics Corporation (NASDAQ:UTHR ) Q3 2024 Earnings Conference Call October 30, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairpe...

2 months ago · zacks.com

Here's What Key Metrics Tell Us About United Therapeutics (UTHR) Q3 Earnings

Although the revenue and EPS for United Therapeutics (UTHR) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare w...

2 months ago · zacks.com

United Therapeutics (UTHR) Q3 Earnings and Revenues Top Estimates

United Therapeutics (UTHR) came out with quarterly earnings of $6.39 per share, beating the Zacks Consensus Estimate of $6.18 per share. This compares to earnings of $5.38 per share a year ago.

2 months ago · businesswire.com

United Therapeutics Corporation Reports Third Quarter 2024 Financial Results

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...

Load More News